MCID: LYM008
MIFTS: 46

Lymphangiosarcoma malady

Categories: Rare diseases, Cancer diseases, Immune diseases, Skin diseases

Aliases & Classifications for Lymphangiosarcoma

About this section

Aliases & Descriptions for Lymphangiosarcoma:

Name: Lymphangiosarcoma 10 12 36 65
Skin Lymphangiosarcoma 10 65
Angiosarcoma Associated with Chronic Lymphedema 45
Lymphangiosarcoma of Stewart and Treves 10
Lymphangiosarcoma Following Mastectomy 45
 
Postmastectomy Extremity Angiosarcoma 45
Malignant Lymphangioendothelioma 10
Stewart Treves Syndrome 45
Stewart-Treves Syndrome 10

Classifications:



External Ids:

Disease Ontology10 DOID:2689
NCIt42 C3205, C4490
UMLS65 C0024224, C0346082

Summaries for Lymphangiosarcoma

About this section
Wikipedia:68 Lymphangiosarcoma is a rare malignant tumor which occurs in long-standing cases of primary or secondary... more...

MalaCards based summary: Lymphangiosarcoma, also known as skin lymphangiosarcoma, is related to chronic venous insufficiency and breast juvenile papillomatosis. An important gene associated with Lymphangiosarcoma is TNF (Tumor Necrosis Factor), and among its related pathways are AGE-RAGE signaling pathway in diabetic complications and Signaling events mediated by VEGFR1 and VEGFR2. Affiliated tissues include lymphatic vessels, endothelial and skin, and related mouse phenotypes are liver/biliary system and no phenotypic analysis.

Disease Ontology:10 A lymphatic system cancer that has material basis in endothelial cells located in lymphatic vessels.

Related Diseases for Lymphangiosarcoma

About this section

Diseases related to Lymphangiosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 218)
idRelated DiseaseScoreTop Affiliating Genes
1chronic venous insufficiency30.3TNF, VEGFA, VWF
2breast juvenile papillomatosis10.5HBA1, PROX1
3tufted hair folliculitis10.5FLT4, PROX1
4obesity10.5
5hemangioma thrombocytopenia syndrome10.5FLT4, PROX1
6crohn's disease10.5TNF, VWF
7aorta angiosarcoma10.4HBA1, VEGFA
8type 2n von willebrand disease10.4F8, VWF
9tyrobp-related polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy10.4F8, VWF
10severe hemophilia a10.4F8, VWF
11acral dysostosis dyserythropoiesis syndrome10.4F8, VWF
12turner syndrome10.4FLT4, GJC2, TNF
13hemiplegia alterans10.4FLT4, VEGFA
14brachydactyly10.4FLT4, GJC2
15peyronie's disease10.4TNF, VEGFA
16type 2m von willebrand disease10.4F8, VWF
17orofaciodigital syndrome iii10.4FLT4, PROX1, VEGFC
18von willibrand disease, type 310.4F8, VWF
19selective iga deficiency disease10.4HBA1, TSC1
20angiosarcoma10.4
21gallbladder angiosarcoma10.4CD34, HBA1
22neurofibroma of the esophagus10.3CD34, HBA1
23thyroid sarcoma10.3CD34, HBA1
2415q13.3 microduplication syndrome10.3FLT4, LYVE1
25gastric neuroendocrine neoplasm10.3HBA1, PROX1, VEGFA
26skin angiosarcoma10.3CD34, HBA1
27brawny scleritis10.3CD34, HBA1
28brain stem astrocytic neoplasm10.3CD34, HBA1
29dyskeratosis congenita10.3FLT4, HBA1, VEGFA
30warty dyskeratoma10.3TNF, VEGFA
31omsk hemorrhagic fever10.3FLT4, GJC2, VEGFA
32hypercalcemic sarcoidosis10.3LYZ, TNF
33neurofibroma of gallbladder10.3CD34, DSP
34multifocal osteogenic sarcoma10.3CD34, HBA1
35vaginal villous adenoma10.3CD34, HBA1
36rhinoscleroma10.3LYZ, TNF
37autosomal recessive type iv ehlers-danlos syndrome10.3FLT4, HBA1, PROX1, VEGFC
38refractory plasma cell neoplasm10.3TNF, VEGFA, VWF
39liver lymphoma10.3TNF, VEGFA, VWF
40lymphoblastic lymphoma10.3FLT4, GJC2, PROX1, VEGFC
41enamel erosion10.2CD34, HBA1
42endotheliitis10.2
43benign pericardial teratoma10.2F8, VWF
44asphyxiating thoracic dystrophy10.2DSP, MNX1, TNF
45listeriosis10.2IFNB1, TNF
46tuberculous uveitis10.2LYZ, TNF, VEGFA
47ganglion or cyst of synovium/tendon/bursa10.2CD34, VEGFA
48female reproductive system disease10.2HBA1, LYVE1, PROX1
49benign fibrous mesothelioma10.2CD34, HBA1, VWF
50littre gland carcinoma10.2CD34, HBA1, VWF

Graphical network of the top 20 diseases related to Lymphangiosarcoma:



Diseases related to lymphangiosarcoma

Symptoms for Lymphangiosarcoma

About this section

Drugs & Therapeutics for Lymphangiosarcoma

About this section

Drugs for Lymphangiosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 13)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
PaclitaxelapprovedPhase 2262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
2Albumin-Bound PaclitaxelPhase 22621
3Tubulin ModulatorsPhase 24279
4Antineoplastic Agents, PhytogenicPhase 24294
5Antimitotic AgentsPhase 24296
6
FluorouracilapprovedPhase 1168451-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
7
Belinostatapproved, investigationalPhase 141
Synonyms:
Beleodaq
 
Belinostat
PXD 101
8Immunologic FactorsPhase 118483
9Histone Deacetylase InhibitorsPhase 1532
10Immunosuppressive AgentsPhase 110422
11AntimetabolitesPhase 19454
12AndrogensPhase 11162
13Antimetabolites, AntineoplasticPhase 15770

Interventional clinical trials:

idNameStatusNCT IDPhase
1Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By SurgeryRecruitingNCT00217607Phase 2
2Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid TumorsCompletedNCT00413322Phase 1

Search NIH Clinical Center for Lymphangiosarcoma


Cochrane evidence based reviews: lymphangiosarcoma

Genetic Tests for Lymphangiosarcoma

About this section

Anatomical Context for Lymphangiosarcoma

About this section

MalaCards organs/tissues related to Lymphangiosarcoma:

33
Endothelial, Skin, Brain, Bone, Prostate, Liver, Heart

FMA organs/tissues related to Lymphangiosarcoma:

16
Lymphatic vessels

Animal Models for Lymphangiosarcoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Lymphangiosarcoma:

38 (show all 16)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053708.7FLT4, LYZ, MYC, PROX1, TNF, TSC1
2MP:00030128.3FLT4, IFNB1, LYZ, MYC, TNF, VEGFA
3MP:00028738.2FLT4, GJC2, IFNB1, LYZ, MNX1, MYC
4MP:00053888.2LYZ, MNX1, PDPN, PROX1, TNF, TSC1
5MP:00020068.1CD34, IFNB1, LYZ, MYC, TNF, TSC1
6MP:00053697.7DSP, FLT4, MNX1, MYC, PDPN, TNF
7MP:00107717.2CD34, DSP, FLT4, LYZ, MYC, PDPN
8MP:00053817.2DSP, FLT4, LYZ, MNX1, MYC, PDPN
9MP:00036317.1DSP, GJC2, IFNB1, LYZ, MNX1, MYC
10MP:00053907.1IFNB1, LYZ, MNX1, MYC, PDPN, TNF
11MP:00053846.5CD34, DSP, GJC2, LYVE1, LYZ, MNX1
12MP:00107685.9DSP, F8, FLT4, GJC2, LYZ, MNX1
13MP:00053855.7DSP, FLT4, LYVE1, LYZ, MNX1, MYC
14MP:00053765.5CD34, F8, FLT4, IFNB1, LYZ, MNX1
15MP:00053974.9CD34, F8, GJC2, IFNB1, LYVE1, LYZ
16MP:00053874.6CD34, F8, FLT4, GJC2, IFNB1, LYVE1

Publications for Lymphangiosarcoma

About this section

Articles related to Lymphangiosarcoma:

(show top 50)    (show all 160)
idTitleAuthorsYear
1
Overexpression of miR-595 and miR-1246 in the sera of patients with active forms of inflammatory bowel disease. (25628040)
2015
2
Decreased baseline variability on fetal heart rate pattern in a fetus with heterotaxy syndrome. (26421346)
2015
3
Fast-growing 'giant' clear cell acanthoma detected by dermoscopy during treatment with infliximab in a psoriatic patient. (24750337)
2014
4
Mechanism of NLRP3 inflammasome activation. (24840700)
2014
5
Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis. (24634132)
2014
6
Difference in the ratio of high-molecular weight (HMW) to total adiponectin and HMW adiponectin in late post-menopausal women. (23765418)
2013
7
Development and validation of the disease-specific Short Bowel Syndrome-Quality of Life (SBS-QoL) scale. (23274148)
2013
8
Scientific Evaluation of Edible Fruits and Spices Used for the Treatment of Peptic Ulcer in Traditional Iranian Medicine. (24066235)
2013
9
Migraine prevalence, socioeconomic status, and social causation. (23990405)
2013
10
Management of sickle cell disease from childhood through adulthood. (24094945)
2013
11
Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer. (23825230)
2013
12
Stat3 inhibits PTPN13 expression in squamous cell lung carcinoma through recruitment of HDAC5. (24191246)
2013
13
Low-level laser therapy improves crescentic glomerulonephritis in rats. (23139073)
2013
14
Phagocytes and humoral immunity to pneumonic plague. (22782760)
2012
15
A pilot study of the effects of gonadotropin-releasing hormone agonist therapy on brain activation pattern in a man with pedophilia. (21518701)
2012
16
Predicting death in patients with acetaminophen-induced acute liver failure: the King's College Hospital model is on the SOFA, not the mat. (22253086)
2012
17
HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells. (23023232)
2012
18
Induction of blood lymphocyte cytochrome P450 2E1 in early stage alcoholic liver cirrhosis. (20843640)
2011
19
Differential Dynamics of ATR-Mediated Checkpoint Regulators. (20847938)
2010
20
Association of estrogen receptor alpha and interleukin-10 gene polymorphisms with endometriosis in a Chinese population. (18687423)
2009
21
Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists. (19632830)
2009
22
Multiple endocrine neoplasias: advances and challenges for the future. (19522821)
2009
23
Dysfunction of ouabain-induced cardiac contractility in mice with heart-specific ablation of Na,K-ATPase beta1-subunit. (19683723)
2009
24
Necrotizing haemorrhagic pneumonia proves fatal in an immunocompetent child due to Panton-Valentine Leucocidin, toxic shock syndrome toxins 1 and 2 and enterotoxin C-producing Staphylococcus aureus. (18532937)
2008
25
Glial cytoplasmic inclusions and tissue injury in multiple system atrophy: A quantitative study in white matter (olivopontocerebellar system) and gray matter (nigrostriatal system). (18312549)
2008
26
Midkine enhances soft-tissue sarcoma growth: a possible novel therapeutic target. (18698021)
2008
27
Fetal megalourethra associated with hypoplastic left heart and imperforate anus: a previously unreported association. (18049081)
2008
28
Structure-function-rescue: the diverse nature of common p53 cancer mutants. (17401432)
2007
29
Surgical repair of an aberrant splenic artery aneurysm: report of a case. (17349366)
2007
30
Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up. (17585213)
2007
31
Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes. (16801577)
2006
32
Crossover comparison of timolol and latanoprost in chronic primary angle-closure glaucoma. (14769594)
2004
33
Left atrial phaeochromocytoma. (15486108)
2004
34
Interactions between intermediate snail hosts of the genus Bulinus and schistosomes of the Schistosoma haematobium group. (11769287)
2001
35
PDZ-dependent activation of nitric-oxide synthases by the serotonin 2B receptor. (10734074)
2000
36
Imaging in acute pyelonephritis. American College of Radiology. ACR Appropriateness Criteria. (11037483)
2000
37
Inhibition of agonist-induced p42 and p38 mitogen-activated protein kinase phosphorylation and CD40 ligand/P-selectin expression by cyclic nucleotide-regulated pathways in human platelets. (11008134)
2000
38
Adenocarcinoma in situ of the fallopian tube. A case report. (9850661)
1998
39
A revision of the lissencephaly and Miller-Dieker syndrome critical regions in chromosome 17p13.3. (9063734)
1997
40
Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. (9119882)
1997
41
Interactions between dystrophin and the sarcolemma membrane. (9210217)
1997
42
Lymphangiosarcoma in a young dog. (8740713)
1996
43
Double outlet right ventricle with unprotected pulmonary vasculature presenting in a woman of 65. (8795489)
1996
44
BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. (8383682)
1993
45
Changes in bone inducing activity of bone morphogenetic protein with aging. (8154837)
1993
46
Surgical manifestations and management of ascariasis in Kashmir. (1401971)
1992
47
Clinical and experimental studies on vitronectin in bacterial pneumonia]. (1698210)
1990
48
Acatalasia discovered by accident during a disk operation. (3382341)
1988
49
Genetic variation of Murray Valley encephalitis virus. (2841405)
1988
50
Chemotherapy as prophylaxis against secondary intestinal tuberculosis; a report of 150 autopsies. (14885673)
1951

Variations for Lymphangiosarcoma

About this section

Expression for genes affiliated with Lymphangiosarcoma

About this section
Search GEO for disease gene expression data for Lymphangiosarcoma.

Pathways for genes affiliated with Lymphangiosarcoma

About this section

GO Terms for genes affiliated with Lymphangiosarcoma

About this section

Biological processes related to Lymphangiosarcoma according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of protein complex assemblyGO:003133410.5TNF, VEGFA
2lymph vessel developmentGO:000194510.5FLT4, PROX1
3induction of positive chemotaxisGO:005093010.2VEGFA, VEGFC
4positive regulation of protein autophosphorylationGO:003195410.2VEGFA, VEGFC
5positive regulation of mesenchymal cell proliferationGO:000205310.1MYC, VEGFA
6cellular response to vascular endothelial growth factor stimulusGO:00359249.9FLT4, VEGFA
7negative regulation of viral genome replicationGO:00450719.9IFNB1, PROX1, TNF
8positive regulation of cellular component movementGO:00512729.9PDPN, VEGFA
9positive regulation of neuroblast proliferationGO:00020529.8VEGFA, VEGFC
10platelet degranulationGO:00025769.8VEGFA, VEGFC, VWF
11cell-matrix adhesionGO:00071609.5CD34, LYVE1, TSC1
12positive regulation of angiogenesisGO:00457669.4CD34, VEGFA, VEGFC
13blood coagulationGO:00075969.3F8, IFNB1, VEGFA, VEGFC
14lung developmentGO:00303249.1PDPN, PROX1, VEGFA
15single organismal cell-cell adhesionGO:00163379.0CD34, DSP, PDPN
16positive regulation of transcription from RNA polymerase II promoterGO:00459448.5IFNB1, MYC, PROX1, TNF, VEGFA

Sources for Lymphangiosarcoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet